cms glp 1 coverage Why Medicare Won't Cover GLP-1 Drugs for Weight Loss Medicare Spending on Ozempic and

Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-nave people with type 2 diabetes: the DUAL IV trial

Sci Rep 7

The American Diabetes Association (ADA) guidelines updated in 2023 recommend GLP-1 receptor agonists as a preferred treatment option for many patients with type 2 diabetes, particularly those with or at high risk for cardiovascular disease or kidney disease

Reduced inflammation may be one of the reasons, including weight loss and better blood sugar control, why

Both cause similar side effects, primarily gastrointestinal issues like nausea, diarrhea, and constipation

Compounded semaglutide and tirzepatide are not FDA-approved, and are used off-label when clinically appropriate